Metagenomi Therapeutics, Inc.
corporate_fare Company Profile
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for MGX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 11 most recent items scored 7 or higher, the top rating is 8/10, with 4 rated 8 or above. Recent SEC coverage for MGX spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Metagenomi Q3: $101.7M Cash, Loss Narrows to $21.1M, $7.5M Securities Settlement
- FDA Clears Metagenomi's MGX-001 IND for Hemophilia A; Cash Runway Extended Into 2028
- FDA Clears IND for One-Time Hemophilia A Gene Editing Therapy; Cash Runway Into 2028
- Metagenomi Q2 Revenue Turns Negative on Ionis Catch-Up; Cash Burn Accelerates
- Metagenomi Reports Q2 Cash of $120.7M, Runway Through Q4 2027; IND Filing on Track
Financial Snapshot
Short Interest & Short Volume
11.13 days to coverFINRA reported short interest of 1,329,414 shares in MGX as of the October 30, 2026 settlement, a 2.9% increase from the prior period — about 11.1 days to cover at its recent average daily volume. On November 19, 2026, 28.8% of MGX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.